sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
Published 4 years ago • 1.8K plays • Length 6:43Download video MP4
Download video MP3
Similar videos
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
4:56
optimizing outcomes in egfr mutation-positive nsclc with tkis
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:50
sequencing with osimertinib in egfr-mutated nsclc
-
6:02
egfr mutation and cancer
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
10:03
surgical technologies, newer drugs have changed the face of oncology: prof. (dr) suresh h advani
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
7:08
emerging data in egfr-mutant lung cancer
-
1:35
afatinib for advanced egfrm-positive nsclc
-
45:43
egfr mutant lung cancer: 2013 update
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
8:11
advances in frontline therapy for egfr nsclc
-
3:38
overview of the world of egfr mutant lung cancers
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
3:31
shifting prognoses of patients with egfr-mutant nsclc
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:53
resistance to osimertinib in egfr-mutated nsclc